[Prognostic value of bone marrow hematogones in childhood B-lineage acute lymphoblastic leukemia].
OBJECTIVE
To study the prognostic value of hematogones (HGs) for childhood B-lineage acute lymphoblastic leukemia (B-ALL) during consolidation chemotherapy.


METHODS
A retrospective analysis was conducted for 196 children with newly-diagnosed B-ALL. They were divided into high-risk group (n=55), intermediate-risk group (n=69), and low-risk group (n=72) by risk stratification, and into complete remission group (n=165) and relapse group (n=31) by clinical outcome. The European BIOMED-1 standard flow cytometry for minimal residual disease (MRD) was used to determine the number of HGs during consolidation chemotherapy. The Kaplan-Meier survival curve was used to assess event-free survival (EFS).


RESULTS
The high-risk group had a significantly lower number of HGs than the intermediate-risk and low-risk groups (P<0.05). The number of HGs in the complete remission group was significantly higher than in the relapse group (P<0.05). The children with HGs ≤1.0% had a significantly lower EFS than those with HGs <1.0% (P<0.05).


CONCLUSIONS
HGs can be used to assess the treatment outcome and prognosis in children with B-ALL, and proliferation of HGs reflects the good effect of chemotherapy in such children.
Department of Laboratory Medicine, West China Second University Hospital, Sichuan University, Chengdu 610041, China. jiangyongmei-1@163.com.
Yue-Fan
YF
Wang
Yong-Mei
YM
Jiang
Ju
J
Gao
Ping
P
Zhou
Ge
G
Zhang
D000293:Adolescent; D001853:Bone Marrow / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007223:Infant; D008297:Male; D018365:Neoplasm, Residual; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality* / Q000473:pathology; D011379:Prognosis; D012189:Retrospective Studies